Neoangiogenesis and expression of hypoxia-inducible factor 1α, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas

Gynecologic Oncology

Volumn 108, Issue 3, 2008, Pages 603-608

  Ozbudak, Irem Hicran ^a   Karaveli, Seyda ^a   Simsek, Tayyup ^a   Erdogan, Gulgun ^a   Pestereli, Elif ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Endometrium adenocarcinoma; GLUT 1; HIF 1 ; Neoangiogenesis; VEGF

Indexed keywords

CD34 ANTIBODY; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER STAGING; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 39249084048     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.11.028     Document Type: Article

References (25)

1. Prat J. Prognostic parameters of endometrial carcinoma. Hum Pathol 35 (2004) 649-662
2. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3 (2003) 401-410
3. Semenza G.L. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 35 (2000) 71-103
4. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
5. Ferrara N., and vis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18 (1997) 4-25
6. Behrooz A., and Ismail-Beigi F. Stimulation of glucose transport by hypoxia: signals and mechanisms. News Physiol Sci 14 (1999) 105-110
7. Giatromanolaki A., Sivridis E., Kouskoukis C., Gatter K.C., Harris A.L., and Koukourakis M.I. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 13 (2003) 493-501
8. Airley R.E., Loncaster J., Raleigh J.A., Harris A.L., Davidson S.E., Hunter R.D., et al. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer 104 (3-10-2003) 85-91
9. Weidner N., Semple J.P., Welch W.R., and Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324 (1-3-1991) 1-8
10. Airley R., Loncaster J., Davidson S., Bromley M., Roberts S., Patterson A., et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 7 (2001) 928-934
11. Birner P., Schindl M., Obermair A., Plank C., Breitenecker G., and Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60 (9-1-2000) 4693-4696
12. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59 (11-15-1999) 5830-5835
13. Burri P., Djonov V., Aebersold D.M., Lindel K., Studer U., Altermatt H.J., et al. Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 56 (6-1-2003) 494-501
14. Giatromanolaki A., Koukourakis M.I., Sivridis E., Turley H., Talks K., Pezzella F., et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 85 (9-14-2001) 881-890
15. Koukourakis M.I., Giatromanolaki A., Sivridis E., Simopoulos C., Turley H., Talks K., et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 53 (8-1-2002) 1192-1202
16. Sivridis E., Giatromanolaki A., Gatter K.C., Harris A.L., and Koukourakis MI. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95 (9-1-2002) 1055-1063
17. Semenza G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8 (2002) S62-S67
18. Giatromanolaki A., Sivridis E., Brekken R., Thorpe P.E., Anastasiadis P., Gatter K.C., et al. The angiogenic "vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma: prognostic and therapeutic implications. Cancer 92 (11-15-2001) 2569-2577
19. Seki N., Kodama J., Hongo A., Miyagi Y., Yoshinouchi M., and Kudo T. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression are implicated in the angiogenesis of endometrial cancer. Eur J Cancer 36 (2000) 68-73
20. Mazurek A., and Kuc P. Angiogenesis-prognostic factor in patients with endometrial cancer. Ginekol Pol 76 (2005) 838-845
21. Mazurek A., Kuc P., Terlikowski S., and Laudanski T. Evaluation of tumor angiogenesis and thymidine phosphorylase tissue expression in patients with endometrial cancer. Neoplasma 53 (2006) 242-246
22. Ozalp S., Yalcin O.T., Acikalin M., Tanir H.M., Oner U., and Akkoyunlu A. Microvessel density (MVD) as a prognosticator in endometrial carcinoma. Eur J Gynaecol Oncol 24 (2003) 305-308
23. Ito T., Noguchi Y., Satoh S., Hayashi H., Inayama Y., and Kitamura H. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol 11 (1998) 437-443
24. Noguchi Y., Marat D., Saito A., Yoshikawa T., Doi C., Fukuzawa K., et al. Expression of facilitative glucose transporters in gastric tumors. Hepatogastroenterology 46 (1999) 2683-2689
25. Haber R.S., Rathan A., Weiser K.R., Pritsker A., Itzkowitz S.H., Bodian C., et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 83 (7-1-1998) 34-40